支气管哮喘治疗年度进展2022  

Annual progress in treatment of bronchial asthma 2022

作　　者：黄华琼[1] 沈华浩[1] Huang Huaqiong;Shen Huahao

机构地区：[1]浙江省呼吸疾病诊治及研究重点实验室、浙江大学医学院附属第二医院呼吸与危重症医学科,杭州310009

出　　处：《中华结核和呼吸杂志》2023年第1期55-61,共7页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：支气管哮喘(简称哮喘)是最常见的慢性炎症性气道疾病之一。全球哮喘的发病率逐年升高,对社会和个人造成了沉重的医疗负担,也促进相关诊疗策略不断改善。随着哮喘基础研究的持续推进,循证证据不断涌现,哮喘的治疗领域也出现了新的药物、观点和策略。本文综述了2021年10月1日至2022年9月30日哮喘治疗领域的进展和成果,以及多个更新的指南、共识对哮喘的指导意见,为哮喘的治疗提供临床视角的思考。Bronchial asthma is one of the most common chronic inflammatory airway diseases.Its incidence is increasing annually worldwide,posing a heavy medical burden to society and individuals.At the same time,continuous improvement has been made in the diagnosis and treatment strategies of asthma.With the advancement of basic research and the emergence of evidence-based evidence on asthma,new drugs,updated ideas and strategies have appeared in the field of asthma treatment.This article reviewed the progress and achievements in the field of asthma treatment from 1st October 2021 to 30th September 2022,as well as several updated guidelines and consensus guidance on asthma,providing clinical perspective for the treatment of asthma.

关 键 词：医疗负担 气道疾病 哮喘治疗 诊疗策略 支气管哮喘 慢性炎症 持续推进 

分 类 号：R562.25[医药卫生—呼吸系统]